FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385799286> ?p ?o ?g. }

• W4385799286 abstract "We report the results of the French multicentric phase II study MIITOP (NCT00960739), which evaluated tandem infusions of 131 I-metaiodobenzylguanidine (mIBG) and topotecan in children with relapsed/refractory metastatic neuroblastoma (NBL).Patients received 131 I-mIBG on day 1, with intravenous topotecan daily on days 1-5. A second activity of 131 I-mIBG was given on day 21 to deliver a whole-body radiation dose of 4 Gy, combined with a second course of topotecan on days 21-25. Peripheral blood stem cells were infused on day 31.Thirty patients were enrolled from November 2008 to June 2015. Median age at diagnosis was 5.5 years (2-20). Twenty-one had very high-risk NBL (VHR-NBL), that is, stage 4 NBL at diagnosis or at relapse, with insufficient response (i.e., less than a partial response of metastases and more than three mIBG spots) after induction chemotherapy; nine had progressive metastatic relapse. Median Curie score at inclusion was 6 (1-26). Median number of prior lines of treatment was 3 (1-7). Objective response rate was 13% (95% confidence interval [CI]: 4-31) for the whole population, 19% for VHR-NBL, and 0% for progressive relapses. Immediate tolerance was good, with nonhematologic toxicity limited to grade-2 nausea/vomiting in eight patients. Two-year event-free survival was 17% (95% CI: 6-32). Among the 16 patients with VHR-NBL who had not received prior myeloablative busulfan-melphalan consolidation, 13 had at least stable disease after MIITOP; 11 subsequently received busulfan-melphalan; four of them were alive (median follow-up: 7 years).MIITOP showed acceptable tolerability in this heavily pretreated population and encouraging survival rates in VHR-NBL when followed by busulfan-melphalan." @default.
• W4385799286 created "2023-08-15" @default.
• W4385799286 creator A5004458586 @default.
• W4385799286 creator A5009669400 @default.
• W4385799286 creator A5014527301 @default.
• W4385799286 creator A5017308862 @default.
• W4385799286 creator A5039972816 @default.
• W4385799286 creator A5044751261 @default.
• W4385799286 creator A5044769167 @default.
• W4385799286 creator A5046444031 @default.
• W4385799286 creator A5053948279 @default.
• W4385799286 creator A5067966229 @default.
• W4385799286 creator A5068789149 @default.
• W4385799286 creator A5069253505 @default.
• W4385799286 creator A5072160244 @default.
• W4385799286 creator A5072347237 @default.
• W4385799286 creator A5083818934 @default.
• W4385799286 date "2023-08-13" @default.
• W4385799286 modified "2023-10-09" @default.
• W4385799286 title "Phase II study of ¹³¹I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP" @default.
• W4385799286 cites W1101533912 @default.
• W4385799286 cites W1818531089 @default.
• W4385799286 cites W1894683927 @default.
• W4385799286 cites W1964456895 @default.
• W4385799286 cites W1982238493 @default.
• W4385799286 cites W1982294823 @default.
• W4385799286 cites W1985200617 @default.
• W4385799286 cites W2005324578 @default.
• W4385799286 cites W2029590939 @default.
• W4385799286 cites W2046209641 @default.
• W4385799286 cites W2056762938 @default.
• W4385799286 cites W2059844864 @default.
• W4385799286 cites W2064907862 @default.
• W4385799286 cites W2072328760 @default.
• W4385799286 cites W2090031769 @default.
• W4385799286 cites W2091158789 @default.
• W4385799286 cites W2098908781 @default.
• W4385799286 cites W2118171008 @default.
• W4385799286 cites W2127775057 @default.
• W4385799286 cites W2132163676 @default.
• W4385799286 cites W2138655697 @default.
• W4385799286 cites W2147800896 @default.
• W4385799286 cites W2592061165 @default.
• W4385799286 cites W2611071372 @default.
• W4385799286 cites W2618869560 @default.
• W4385799286 cites W2767789735 @default.
• W4385799286 cites W2947466568 @default.
• W4385799286 cites W3018670999 @default.
• W4385799286 cites W3088706923 @default.
• W4385799286 cites W3154434101 @default.
• W4385799286 cites W3179702411 @default.
• W4385799286 cites W4281683415 @default.
• W4385799286 cites W84978199 @default.
• W4385799286 doi "https://doi.org/10.1002/pbc.30615" @default.
• W4385799286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37574821" @default.
• W4385799286 hasPublicationYear "2023" @default.
• W4385799286 type Work @default.
• W4385799286 citedByCount "0" @default.
• W4385799286 crossrefType "journal-article" @default.
• W4385799286 hasAuthorship W4385799286A5004458586 @default.
• W4385799286 hasAuthorship W4385799286A5009669400 @default.
• W4385799286 hasAuthorship W4385799286A5014527301 @default.
• W4385799286 hasAuthorship W4385799286A5017308862 @default.
• W4385799286 hasAuthorship W4385799286A5039972816 @default.
• W4385799286 hasAuthorship W4385799286A5044751261 @default.
• W4385799286 hasAuthorship W4385799286A5044769167 @default.
• W4385799286 hasAuthorship W4385799286A5046444031 @default.
• W4385799286 hasAuthorship W4385799286A5053948279 @default.
• W4385799286 hasAuthorship W4385799286A5067966229 @default.
• W4385799286 hasAuthorship W4385799286A5068789149 @default.
• W4385799286 hasAuthorship W4385799286A5069253505 @default.
• W4385799286 hasAuthorship W4385799286A5072160244 @default.
• W4385799286 hasAuthorship W4385799286A5072347237 @default.
• W4385799286 hasAuthorship W4385799286A5083818934 @default.
• W4385799286 hasBestOaLocation W43857992861 @default.
• W4385799286 hasConcept C121332964 @default.
• W4385799286 hasConcept C126322002 @default.
• W4385799286 hasConcept C141071460 @default.
• W4385799286 hasConcept C142424586 @default.
• W4385799286 hasConcept C143998085 @default.
• W4385799286 hasConcept C2776694085 @default.
• W4385799286 hasConcept C2776715637 @default.
• W4385799286 hasConcept C2776755627 @default.
• W4385799286 hasConcept C2778684742 @default.
• W4385799286 hasConcept C2778822529 @default.
• W4385799286 hasConcept C2780580376 @default.
• W4385799286 hasConcept C2780611847 @default.
• W4385799286 hasConcept C2781209748 @default.
• W4385799286 hasConcept C2908647359 @default.
• W4385799286 hasConcept C31760486 @default.
• W4385799286 hasConcept C54355233 @default.
• W4385799286 hasConcept C71924100 @default.
• W4385799286 hasConcept C81885089 @default.
• W4385799286 hasConcept C86803240 @default.
• W4385799286 hasConcept C87355193 @default.
• W4385799286 hasConcept C99454951 @default.
• W4385799286 hasConceptScore W4385799286C121332964 @default.
• W4385799286 hasConceptScore W4385799286C126322002 @default.
• W4385799286 hasConceptScore W4385799286C141071460 @default.
• W4385799286 hasConceptScore W4385799286C142424586 @default.

• next